NCT05428007 2026-01-05Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV MelanomaNYU Langone HealthPhase 2 Recruiting105 enrolled
NCT05704634 2025-10-27A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.M.D. Anderson Cancer CenterPhase 1 Active not recruiting56 enrolled